Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre Phase III Study to Evaluate Pre-emptive Tenofovir for Prevention of Hepatitis B Virus Reactivation in HBsAg Negative/Anti-HBc Positive Individuals Undergoing Anti-CD20-based Chemotherapy for Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

NCT02186574 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT02186574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02186574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre Phase III Study to Evaluate Pre-emptive Tenofovir for Prevention of Hepatitis B Virus Reactivation in HBsAg Negative/Anti-HBc Positive Individuals Undergoing Anti-CD20-based Chemotherapy for Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
Lead sponsor
University Health Network, Toronto
Phase
Phase 3
Overall status
Unknown status
Start date
May 31, 2015
Completion date
February 28, 2021
Enrollment
184 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b, lymphoma, non-hodgkin